Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.1470
+0.0005 (0.34%)
Sep 4, 2026, 5:29 PM CET
Prostatype Genomics AB Market Cap
Prostatype Genomics AB has a market cap or net worth of 82.33 million as of September 4, 2026. Its market cap has increased by 277.15% in one year.
Market Cap
82.33M
Enterprise Value
81.94M
Revenue
1.01M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.15
ChartMarket Cap Chart
Since November 3, 2020, Prostatype Genomics AB's market cap has decreased from 92.30M to 82.33M, a decrease of -10.80%. That is a compound annual growth rate of -1.94%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 4, 2026 | 82.33M | 363.67% |
| Dec 30, 2025 | 17.76M | -76.14% |
| Dec 30, 2024 | 74.42M | 555.78% |
| Dec 29, 2023 | 11.35M | -76.58% |
| Dec 30, 2022 | 48.46M | -64.07% |
| Dec 30, 2021 | 134.89M | -28.46% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 3, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Swedish Orphan Biovitrum AB | 158.02B |
| Getinge AB | 66.73B |
| Sectra AB | 55.18B |
| Medicover AB | 37.08B |
| Annexin Pharmaceuticals AB | 95.65M |
| Spago Nanomedical AB | 89.82M |
| IDL Diagnostics AB | 89.61M |
| Immunovia AB | 89.33M |